12:00 AM
 | 
Oct 25, 2010
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Biocon, Pfizer sales and marketing update

Biocon partnered with Pfizer to market Biocon's biosimilar versions of insulin and insulin analog products, including recombinant human insulin, glargine, aspart and lispro. The companies will share co-exclusive rights in Germany, India and Malaysia, while Pfizer...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >